the note

Merck and Moderna announced this week that their personalized cancer vaccine has shown significant success in patients with melanoma. The vaccine works. (I am not making this up.)

This requires some explanation, because the phrase "personalized cancer vaccine" sounds like the kind of thing a wellness company prints on a water bottle. The word "personalized" now describes Netflix recommendations, fountain drink sizes, and greeting cards generated by artificial intelligence. In this case it means something different. It means the vaccine is built for you. And the material used to build it comes from your cancer.

Here is how it works: a doctor takes a biopsy of your tumor. Researchers sequence the DNA of the cancer cells, looking for the specific mutations — the exact ways your cancer has changed from normal tissue. Those mutations are fingerprints. They are yours and no one else's. A facility manufactures an mRNA vaccine targeted at those fingerprints. The vaccine is then administered to you. Your immune system, which had been operating under the impression that these mutated cells were part of you, is now informed otherwise. It kills them.

The vaccine is made from the information your cancer provided. The cancer has written its own warrant.

The company that made this is Moderna. This is worth a moment. In 2020 and 2021, Moderna built one vaccine for eight billion people. One sequence. Everyone on the planet was offered the same thing. (The debates about this were quite involved.) Now, using the same mRNA platform, the same basic technology, the same company — they are making a completely different product for every single patient who receives this treatment. The input changes every time. The factory takes your tumor's mutation profile as instructions and returns to you something that has never been made before and will never be made again.

This is technically the opposite of scale.

For most of the past century, oncology worked by finding something cancer had in common with itself — a shared pathway, a protein found across tumor types, a vulnerability that, if blocked, interrupted growth. Chemotherapy. Targeted therapy. Checkpoint inhibitors. The goal was to find the universal flaw in cancer as a category. The personalized vaccine starts from the other end. It says: your cancer is not like other cancers. Its mutations are specific to it. The approach is not to find what all cancers share but to look at what makes yours uniquely yours, and then build the weapon from that.

The practical implication is that this approach — if it works across cancer types, which is what researchers are now testing — will require manufacturing a completely custom pharmaceutical product for every patient who receives it. The timeline from biopsy to vaccine is weeks. Each one involves DNA sequencing, algorithmic selection of the right mutations, and mRNA synthesis from scratch. This is not how pharmaceutical companies currently operate at scale. Pharmaceutical companies currently operate by making the same pill very many times, which is why pills are cheap. A vaccine made once for one person, from that person's own cancer, is a different category of object.

The results in melanoma are described as promising. Recurrence rates dropped significantly in patients who received the vaccine alongside standard immunotherapy. The researchers are now testing the approach in lung cancer, bladder cancer, kidney cancer, and others — each of which would require its own set of personalized vaccines, made from the mutations inside those specific tumors.

The cancer, asked for comment, has left a full record of its mutations on file. Researchers are reviewing it.